source
- Genmab’s Rina-S ADC shows 9.5-month median PFS, touted as superior to AbbVie’s ElahereGenmab reported median progression‑free survival of 9.5 months for its FRα‑directed antibody‑drug conjugate Rina‑S in part C of the phase 1/2 Rainfol‑01 trial, which enrolled 109 patients with plat…
- Viking Therapeutics jumps 24% after Phase 1 obesity data, Longeveron falls 64% on mid-stage setbackIn September biotech stocks showed wide swings, with Viking Therapeutics gaining 24% and Longeveron dropping 64% as investors reacted to clinical data and trial setbacks. Viking reported Phase 1 r…